Research programme: anti-cancer therapeutics - Janssen/Vaccinex
Latest Information Update: 04 Dec 2014
At a glance
- Originator Janssen Research & Development; Vaccinex
- Class Monoclonal antibodies
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Cancer
Most Recent Events
- 02 Dec 2014 Early research in Cancer in USA (Parenteral)